{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:48:26Z","timestamp":1784130506366,"version":"3.55.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011408","name":"USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bpobgyn.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T02:32:50Z","timestamp":1504665170000},"page":"42-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-3105","authenticated-orcid":false,"given":"Julia M.L.","family":"Brotherton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.bpobgyn.2017.08.010_bib1","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s13669-015-0136-9","article-title":"HPV vaccination: current global status","author":"Brotherton","year":"2015","journal-title":"Curr Obstet Gynecol Rep"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s13669-016-0165-z","article-title":"Primary prevention of HPV through vaccination: update on current global status","author":"Brotherton","year":"2016","journal-title":"Curr Obst Gynecol Rep"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib4","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A\u00a0pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agents Cancer"},{"issue":"6","key":"10.1016\/j.bpobgyn.2017.08.010_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib8","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J\u00a0Adolesc Health"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.bpobgyn.2017.08.010_bib11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.bpobgyn.2017.08.010_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1586\/14760584.2016.1124763","article-title":"Human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases","volume":"15","author":"Skinner","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib16","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1016\/j.vaccine.2017.06.028","article-title":"Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: a systematic review and meta-analysis","volume":"35","author":"Bissett","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.bpobgyn.2017.08.010_bib18","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.bpobgyn.2017.08.010_bib19","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib20","doi-asserted-by":"crossref","unstructured":"Das R et\u00a0al. Effectiveness, immunogenicity, and safety of Gardasil\u2122 in pre-adolescents and adolescents- 10 years of follow-up. EUROGIN 2016. Available at: http:\/\/eurogin.com\/2016\/images\/doc\/eurogin-2016-abstracts-part-2.pdf, [Accessed August 2017].","DOI":"10.1016\/j.jadohealth.2015.10.035"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pvr.2017.03.002","article-title":"Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine \u2013 a combined analysis of five phase III clinical trials","volume":"3","author":"Peterson","year":"2017","journal-title":"Papillomavirus Res"},{"issue":"22","key":"10.1016\/j.bpobgyn.2017.08.010_bib22","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.vaccine.2017.03.096","article-title":"Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis","volume":"35","author":"D'Addario","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib23","series-title":"Human papillomavirus vaccines: WHO position paper","author":"World Health Organization","year":"2014"},{"issue":"7","key":"10.1016\/j.bpobgyn.2017.08.010_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV- 16\/18 AS04 adjuvanted vaccine: combined analysis of data from the Cosa Rica vaccine trial and the PATRICIA","volume":"16","author":"Kreimer","year":"2015","journal-title":"Trial Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.bpobgyn.2017.08.010_bib26","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A\u00a0review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ (Clin Res ed)"},{"issue":"12","key":"10.1016\/j.bpobgyn.2017.08.010_bib28","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","author":"Hildesheim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2\u20133)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib31","first-page":"393","article-title":"Offering HPV vaccination to women treated for high-grade cervical intraepithelial neoplasia: what you need to know","volume":"54","author":"Brotherton","year":"2014","journal-title":"ANZJOG"},{"issue":"8","key":"10.1016\/j.bpobgyn.2017.08.010_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A\u00a09-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N\u00a0Eng J Med"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib33","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"},{"issue":"48","key":"10.1016\/j.bpobgyn.2017.08.010_bib34","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Castellsagu\u00e9","year":"2015","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.bpobgyn.2017.08.010_bib35","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-Dose regimens in girls and boys vs a 3-Dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.bpobgyn.2017.08.010_bib36","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1017\/S0950268817000747","article-title":"Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence","volume":"145","author":"Signorelli","year":"2017","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib37","unstructured":"Gardasil 9. Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003852\/WC500189111.pdf. [Accessed August 2017]."},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cct.2016.10.006","article-title":"Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine","volume":"52","author":"Luxembourg","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv282","article-title":"Health and economic impact of switching from a 4-Valent to a 9-Valent HPV vaccination program in the United States","volume":"108","author":"Brisson","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib40","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ijc.28541","article-title":"Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine","volume":"134","author":"Drolet","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib41","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12\u201326 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.bpobgyn.2017.08.010_bib42","first-page":"393","article-title":"Meeting of the global advisory committee on vaccine safety, 7\u20138 June 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"WER"},{"issue":"5","key":"10.1016\/j.bpobgyn.2017.08.010_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/pds.3554","article-title":"Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.bpobgyn.2017.08.010_bib44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/INF.0000000000000793","article-title":"An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015","volume":"34","author":"Vichnin","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"29","key":"10.1016\/j.bpobgyn.2017.08.010_bib45","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.vaccine.2015.04.014","article-title":"Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine","volume":"33","author":"Goss","year":"2015","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.bpobgyn.2017.08.010_bib46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa1612296","article-title":"Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes","volume":"376","author":"Scheller","year":"2017","journal-title":"N.\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.bpobgyn.2017.08.010_bib47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"issue":"17","key":"10.1016\/j.bpobgyn.2017.08.010_bib48","first-page":"457","article-title":"Syncope after vaccination\u2013United States, january 2005-july 2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J\u00a0Autoimmun"},{"issue":"2","key":"10.1016\/j.bpobgyn.2017.08.010_bib50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib53","series-title":"European Medicines agency. Assessment report","year":"2015"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.bpobgyn.2017.08.010_bib55","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib56","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2017.06.031","article-title":"HPV vaccination and risk of chronic fatigue syndrome\/myalgic encephalomyelitis: a nationwide register-based study from Norway","volume":"35","author":"Feiring","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.bpobgyn.2017.08.010_bib57","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/imj.13005","article-title":"Adverse event monitoring of the human papillomavirus vaccines in Scotland","volume":"46","author":"Cameron","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib58","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.vaccine.2013.08.024","article-title":"Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK","volume":"31","author":"Donegan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib59","unstructured":"Phillips A, Patel C, Brotherton JML, et\u00a0al. Safety of human papillomavirus vaccines: an updated review. Drug Ther in press."},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.bpobgyn.2017.08.010_bib61","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/21645515.2016.1168952","article-title":"Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States","volume":"12","author":"Gee","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.bpobgyn.2017.08.010_bib62","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/14740338.2015.1013532","article-title":"Safety of human papillomavirus vaccines: a review","volume":"14","author":"Stillo","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.bpobgyn.2017.08.010_bib63","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12879-017-2361-5","article-title":"Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study","volume":"17","author":"Cocchio","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"39","key":"10.1016\/j.bpobgyn.2017.08.010_bib65","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1016\/j.vaccine.2016.08.020","article-title":"Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): a population-based assessment","volume":"34","author":"Guerra","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.bpobgyn.2017.08.010_bib66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/OLQ.0000000000000418","article-title":"Significant reduction in the incidence of genital warts in young men 5 years into the Danish human papillomavirus vaccination program for girls and women","volume":"43","author":"Bollerup","year":"2016","journal-title":"Sex Transm Dis"},{"issue":"2","key":"10.1016\/j.bpobgyn.2017.08.010_bib67","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2017.06.001","article-title":"Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure","volume":"146","author":"Lurie","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"25","key":"10.1016\/j.bpobgyn.2017.08.010_bib68","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.vaccine.2017.04.080","article-title":"Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain","volume":"35","author":"Navarro-Illana","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib69","article-title":"Human papillomavirus vaccine dose effectiveness against incident genital warts in a cohort of insured US females","author":"Hariri","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.bpobgyn.2017.08.010_bib70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/OLQ.0000000000000615","article-title":"Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of U.S. Adolescents","volume":"44","author":"Perkins","year":"2017","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015021","article-title":"Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study","volume":"7","author":"Lamb","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.bpobgyn.2017.08.010_bib72","first-page":"202","article-title":"Human papillomavirus prevalence in unvaccinated heterosexual men after a national female vaccination program","volume":"215","author":"Machalek","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix436","article-title":"Population-level herd protection of males from a female human papillomavirus vaccination program: evidence from Australian serosurveillance","author":"Pillsbury","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.bpobgyn.2017.08.010_bib74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/infdis\/jix057","article-title":"Prevalence of genital human papillomavirus in males, United States, 2013-2014","volume":"215","author":"Gargano","year":"2017","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.bpobgyn.2017.08.010_bib75","first-page":"757","article-title":"Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France","volume":"215","author":"Heard","year":"2017","journal-title":"J\u00a0Infect Dis"},{"issue":"10","key":"10.1016\/j.bpobgyn.2017.08.010_bib76","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/ciw533","article-title":"Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community","volume":"63","author":"Kahn","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pvr.2017.01.001","article-title":"Human papillomavirus (HPV) in young women in Britain: population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types","volume":"3","author":"Tanton","year":"2017","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib78","doi-asserted-by":"crossref","first-page":"E281","DOI":"10.1503\/cmaj.151528","article-title":"Effect of human papillomavirus vaccination on cervical cancer screening in Alberta","author":"Kim","year":"2016","journal-title":"CMAJ"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix455","article-title":"Declines in HPV-associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, US, 2008-2015","author":"Niccolai","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.bpobgyn.2017.08.010_bib80","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5694\/mja15.01038","article-title":"HPV vaccine impact in Australian women: ready for an HPV based screening program","volume":"204","author":"Brotherton","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib81","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/jech-2017-209113","article-title":"The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap","volume":"71","author":"Cameron","year":"2017","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib82","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12879-016-1347-z","article-title":"Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data","volume":"16","author":"Smith","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.bpobgyn.2017.08.010_bib83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5694\/mja16.00597","article-title":"Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data","volume":"206","author":"Ali","year":"2017","journal-title":"Med J Aust"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib84","unstructured":"PATH, LSTHM. HPV vaccine lessons learned. http:\/\/www.rho.org\/HPVlessons\/. [Accessed 10 August 2017]."},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib85","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2017.06.003","article-title":"What works for human papillomavirus vaccine introduction in low and middle-income countries?","volume":"4","author":"Howard","year":"2017","journal-title":"Papillomavirus Res"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib86","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/s12913-016-1824-5","article-title":"Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014","volume":"16","author":"Ladner","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib87","series-title":"Scaling-up HPV vaccine introduction","author":"WHO","year":"2016"},{"issue":"48","key":"10.1016\/j.bpobgyn.2017.08.010_bib88","first-page":"561","article-title":"Meeting of the strategic advisory group of experts on immunization, october 2016 \u2013 conclusions and recommendations","volume":"91","author":"WHO","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib89","unstructured":"GAVI [webpage]. http:\/\/www.gavi.org\/support\/process\/apply\/. [Accessed 10 August 2017]."},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib90","first-page":"138","article-title":"Interventions to improve HPV vaccine uptake: a systematic review","author":"Walling","year":"2016","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.bpobgyn.2017.08.010_bib91","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/21645515.2015.1125055","article-title":"Interventions to increase HPV vaccination coverage: a systematic review","volume":"12","author":"Smulian","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.bpobgyn.2017.08.010_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072094","article-title":"A\u00a0qualitative analysis of factors influencing hpv vaccine uptake in Soweto, South Africa among adolescents and their caregivers","volume":"8","author":"Katz","year":"2013","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.bpobgyn.2017.08.010_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161846","article-title":"Attitudes, knowledge and factors associated with human papillomavirus (HPV) vaccine uptake in adolescent girls and young women in Victoria, Australia","volume":"11","author":"Tung","year":"2016","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.bpobgyn.2017.08.010_bib94","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.vaccine.2016.01.023","article-title":"Provider communication and HPV vaccination: the impact of recommendation quality","volume":"34","author":"Gilkey","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib95","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pvr.2016.10.001","article-title":"Factors affecting HPV vaccine acceptance in west Austria: do we need to revise the current immunization scheme?","volume":"2","author":"Borena","year":"2016","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib96","series-title":"HPV Vaccine Communication: special considerations for a unique vaccine","author":"WHO","year":"2016"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib97","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1471-2431-12-154","article-title":"Communicating with parents about vaccination: a framework for health professionals","volume":"12","author":"Leask","year":"2012","journal-title":"BMC Pediatr"},{"issue":"31","key":"10.1016\/j.bpobgyn.2017.08.010_bib98","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1016\/j.vaccine.2015.05.078","article-title":"Introduction of a national HPV vaccination program into Bhutan","volume":"33","author":"Dorji","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijgo.12186","article-title":"Progress in HPV vaccination in low- and lower-middle-income countries","volume":"138","author":"LaMontagne","year":"2017","journal-title":"Int J Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.08.010_bib100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1186\/s12889-017-4526-y","article-title":"Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges","volume":"17","author":"Msyamboza","year":"2017","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.bpobgyn.2017.08.010_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149857","article-title":"Highest vaccine uptake after school-based delivery - a county-level evaluation of the implementation strategies for HPV catch-up vaccination in Sweden","volume":"11","author":"Rehn","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib102","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib103","author":"World Health Organization"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib104","doi-asserted-by":"crossref","first-page":"850","DOI":"10.15585\/mmwr.mm6533a4","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 Years \u2014 United States, 2015","volume":"65","author":"Reagan-Steiner","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib105","unstructured":"WHO\/UNICEF Joint Reporting Process [webpage]. Available at: http:\/\/www.who.int\/immunization\/monitoring_surveillance\/routine\/reporting\/en\/. [Last accessed 10 August 2017]."},{"key":"10.1016\/j.bpobgyn.2017.08.010_bib106","series-title":"Monitoring the coverage and impact of human papillomavirus vaccine \u2013 report of WHO meeting","first-page":"237","author":"WHO","year":"2009"},{"issue":"6","key":"10.1016\/j.bpobgyn.2017.08.010_bib107","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5694\/mja16.00958","article-title":"HPV vaccine coverage is increasing in Australia","volume":"206","author":"Brotherton","year":"2017","journal-title":"Med J Aust"},{"issue":"7","key":"10.1016\/j.bpobgyn.2017.08.010_bib108","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S2214-109X(16)30099-7","article-title":"Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis","volume":"4","author":"Bruni","year":"2016","journal-title":"Lancet Glob Health"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T18:54:29Z","timestamp":1719428069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693417301281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":108,"alternative-id":["S1521693417301281"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.08.010","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}